Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 391,632,384
  • Shares Outstanding, K 2,634,594
  • Annual Sales, $ 82,059 M
  • Annual Income, $ 15,119 M
  • 60-Month Beta 0.70
  • Price/Sales 4.76
  • Price/Cash Flow 12.87
  • Price/Book 6.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 1.45
  • Number of Estimates 7
  • High Estimate 1.55
  • Low Estimate 1.33
  • Prior Year 2.58
  • Growth Rate Est. (year over year) -43.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
143.01 +2.30%
on 05/27/20
153.62 -4.76%
on 05/18/20
-1.97 (-1.33%)
since 05/04/20
3-Month
109.16 +34.02%
on 03/23/20
157.00 -6.82%
on 04/23/20
+2.82 (+1.97%)
since 03/04/20
52-Week
109.16 +34.02%
on 03/23/20
157.00 -6.82%
on 04/23/20
+12.57 (+9.40%)
since 06/04/19

Most Recent Stories

More News
Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report

The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.

JNJ : 145.96 (-1.81%)
AZN : 54.24 (-1.38%)
PFE : 35.79 (-1.02%)
MRK : 81.09 (-1.18%)
MRNA : 59.13 (-1.27%)
Novartis' sBLA for Ofatumumab Gets Extended Review From FDA

The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.

BIIB : 299.20 (-1.12%)
JNJ : 145.96 (-1.81%)
TEVA : 12.70 (-1.40%)
NVS : 85.31 (-0.46%)
Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?

Style Box ETF report for JKF

JKF : 101.81 (+0.27%)
JPM : 105.54 (+1.22%)
JNJ : 145.96 (-1.81%)
PG : 118.03 (-0.42%)
VTV : 104.88 (+0.16%)
IWD : 118.78 (+0.19%)
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $148.25, marking a +0.72% move from the previous day.

JNJ : 145.96 (-1.81%)
Myovant Eyes Relugolix Combo Approval for Uterine Fibroids

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.

JNJ : 145.96 (-1.81%)
ABBV : 92.08 (+1.31%)
MYOV : 15.90 (-3.23%)
TAK : 18.38 (-3.52%)
Lilly Begins Coronavirus Study to Evaluate Antibody Therapy

Lilly (LLY) initiates dosing in a phase I study to evaluate an antibody candidate for treating COVID-19.

JNJ : 145.96 (-1.81%)
SNY : 50.14 (+1.13%)
GILD : 75.04 (+0.86%)
LLY : 150.92 (-1.06%)
Psychedelic Drugs Could Potentially Treat Impending Post-lockdown Mental Health Epidemic

, /PRNewswire/ --  Trials are already underway testing the use of psychedelics such as psilocybin, LSD, ketamine, ecstasy and other currently scheduled drugs to predicted to hit after the lockdown...

JNJ : 145.96 (-1.81%)
SHRM.CN : 1.310 (-5.76%)
SHRMF : 0.9691 (-3.04%)
LLY : 150.92 (-1.06%)
NUMI.VN : 0.700 (unch)
LKYSD : 0.5000 (-6.54%)
MMEDF : 0.3575 (-5.42%)
BGHM : 0.4600 (+12.20%)
Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

JNJ : 145.96 (-1.81%)
GILD : 75.04 (+0.86%)
MRK : 81.09 (-1.18%)
ULTA : 250.85 (-0.57%)
BOX : 18.70 (-1.73%)
Monkeys, ferrets offer needed clues in COVID-19 vaccine race

The global race for a COVID-19 vaccine boils down to some critical questions: How much must the shots rev up someone’s immune system to really work? And could revving it the wrong way cause harm?

PFE : 35.79 (-1.02%)
JNJ : 145.96 (-1.81%)
Merck (MRK) Shares Looking Ripe For A Buy

Merck (MRK) Shares Looking Ripe For A Buy

PFE : 35.79 (-1.02%)
MRK : 81.09 (-1.18%)
JNJ : 145.96 (-1.81%)
GILD : 75.04 (+0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 150.77
1st Resistance Point 149.71
Last Price 145.96
1st Support Level 147.02
2nd Support Level 145.39

See More

52-Week High 157.00
Last Price 145.96
Fibonacci 61.8% 138.73
Fibonacci 50% 133.08
Fibonacci 38.2% 127.43
52-Week Low 109.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar